WuXi XDC (HKG: 2268), a joint venture between Wuxi Biologics (HKG: 2269) and WuXi STA, a subsidiary of WuXi AppTec Co., Ltd (SHA: 603259), has entered into a strategic partnership with Shanghai-based antibody drug conjugate (ADC) specialist, Multitude Therapeutics. Additionally, WuXi XDC has signed a memorandum of understanding (MOU) with Shanghai Huilian Biopharmaceutical Co., Ltd, an ADC drug discovery company, to collaborate on new toxin linker technology and provide comprehensive Contract Research, Development, and Manufacturing Organization (CRDMO) services for ADCs.
Under the partnership, WuXi XDC will offer a comprehensive one-stop development platform for biologically conjugated drugs, including end-to-end CRDMO services. The collaboration aims to construct a more efficient ADC technology platform by focusing on innovative T-Moiety linkers, the integration of camptothecin toxin derivatives, achieving high drug-antibody ratio (DAR) values, and other critical aspects. This alliance is designed to empower customers to expedite the discovery of preclinical ADC candidate molecules (PCCs) and the development of novel bio-conjugated drugs, thereby enhancing the efficiency and likelihood of success in drug development.- Flcube.com
